<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619931</url>
  </required_header>
  <id_info>
    <org_study_id>APD791-002</org_study_id>
    <nct_id>NCT00619931</nct_id>
  </id_info>
  <brief_title>A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The APD791-002 study is designed primarily to evaluate the safety, tolerability, and
      pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures to include adverse events, vital signs, 12-lead ECGs, physical examinations, and clinical lab parameters</measure>
    <time_frame>Throughout study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessments</measure>
    <time_frame>Throughout study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessments (e.g., platelet function)</measure>
    <time_frame>Throughout study duration</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>APD791 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>APD791 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>APD791 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>APD791 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>APD791 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD791</intervention_name>
    <description>APD791 or matching placebo in escalating doses</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy men and women
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men and women, ages 19-45

          -  Non smokers

        Exclusion Criteria:

          -  History of a bleeding disorder

          -  Use of any drug known to have an effect on coagulation or clotting or any
             anti-platelet therapy within 2 weeks of the screening

          -  Recently donated blood or had significant blood loss

          -  Current use of a prescription medication

          -  Pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Kisicki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christen M Anderson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.arenapharm.com</url>
    <description>Arena Home Page</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>December 29, 2008</last_update_submitted>
  <last_update_submitted_qc>December 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>c/o: Vice President and Chief Medical Officer</name_title>
    <organization>Arena Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Healthy adult volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>APD791</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

